A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Sponsor
QLT Inc.
Study ID
NCT00042315
Phase
PHASE3
Status
Terminated

Conditions

  • Stage IIIb Non-small Cell Lung Cancer
  • Stage IV Non-small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To determine whether tariquidar + first-line single agent vinorelbine chemotherapy in patients with Stage IIIb/IV NSCLC will, with an acceptable safety profile, significantly improve overall survival compared with placebo + vinorelbine. To compare the effects of tariquidar/vinorelbine with placebo/vinorelbine on tumor response, time to disease progression, performance status, symptom progression, and quality of life in patients with Stage IIIb/IV NSCLC.

Key Dates

Start date
Jun 30, 2002
Status verified
May 2012
Primary completion
Jun 30, 2003
Completion
Jun 30, 2003

Study Design

Enrollment
490 participants
Allocation
RANDOMIZED

Related Studies